Repositioning an Immunomodulatory Drug Vidofludimus as a Farnesoid X Receptor Modulator With Therapeutic Effects on NAFLD

Repositioning an Immunomodulatory Drug Vidofludimus as a Farnesoid X Receptor Modulator With Therapeutic Effects on NAFLD

Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disorder, and yet with no pharmacological treatment approved worldwide. The repositioning of old drugs provides a safe approach for drug development. Vidofludimus, an inhibitor for dihydroorotate dehydrogenase (DHODH)...

Full description

Bibliographic Details
Main Authors: Yanlin Zhu, Shuangshuang Xu, Yi Lu, Yijuan Wei, Benqiang Yao, Fusheng Guo, Xing Zheng, Yumeng Wang, Ying He, Lihua Jin, Yong Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-05-01
Series:Frontiers in Pharmacology
Subjects:
inflammatory bowel disease (IBD)
nuclear receptor
ligand-binding protein
liver metabolism
drug discovery
drug screening
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2020.00590/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2020.00590/full

Similar Items